RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
…
Rockwood Research

Corporate filings · Event Monitor · Free for all

← Back

Vaxcyte, Inc.

PCVX

Biological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0001649094

SHARE:XLINKEDINEMAIL
Revenue FY2025
—
Net Income
$(0.77B)
EPS (Basic)
$-5.63
Net Margin
—
ROE
-28.5%
Total Equity
$2.69B
Shares Out
149M

Vaxcyte, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Revenue & Net Income (10Y)

Margin Trends

Investor Ownership · 6 funds in our universe

FundPosition Value% of AUMQoQ ChgWeight
RA Capital Management
RA Capital Management
$667.0M
4.1%
—
Maverick Capital
Lee Ainslie
$93.8M
0.6%
+17.1%
Adage Capital Management
Adage Capital Management
$51.2M
0.1%
+151.4%
WCM Investment Management
WCM Investment Management
$14.1M
0.0%
+116.2%
Capital Research Global Investors
Capital Research Global Investors
$48.6M
0.0%
(8.3%)
Bridgewater Associates
Bridgewater Associates
$2.9M
0.0%
+289.2%

Insider Transactions

Reading stored insider transactions…